Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young Adults

Phase 2

Completed

• Conditions: Influenza; Virus Diseases
• Interventions: Biological: UMN-0501

• Registration Number: NCT00980447
• Lead Sponsor: UMN Pharma Inc.

Brief Summary

UMN-0501 is a purified recombinant influenza HA vaccine (A H5N1/Vietnam/1203/2004).

The purpose of the present study is to evaluate immunogenicity, safety and optimal dose among three different doses of UMN-0501 following two same-dose vaccinations of UMN-0501 per patient with a 3 week interval between vaccination in healthy young adults.

Immunogenicity will be confirmed by both microneutralization (MN) antibody and hemagglutination inhibition (HAI) titer levels in the serums of subjects after receiving different doses of UMN-0501. There will be three dose groups with 30 subjects per group for a total of 90 healthy young adults aged 20-40 years enrolled in this study.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2009-09-17
• Study First Submitted QC: 2009-09-18
• Study First Posted: 2009-09-21
• Study Start: 2009-10
• Primary Completion: 2009-12
• Study Completion: 2009-12
• Status Verified: 2010-02
• Last Update Submitted: 2010-02-05
• Last Update Posted: 2010-02-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

• Healthy adult as determined by medical history, physical examination, laboratory test, and clinical judgment of the investigator.
• Males and females aged 20-40 years.
• Provides signed informed consent form after received a detailed explanation of the study protocol prior to any study procedures.

Exclusion Criteria

• Body Mass Index (BMI) 30 kg/m2 and above.
• Has a history of a A/H5N1 influenza virus infection and subjects had received other A/H5N1 influenza vaccine.
• Has a history of allergic reaction by food and medicine including vaccine, and acute fever illness (greater than 39.0C) within 2 days of vaccination.
• Has a history of Guillain-Barre syndrome or acute disseminated encephalomyelitis (ADEM).
• Has severe allergic diseases.
• Has asthma.
• Has a history of convulsions.
• Has a history of any serious disease.
• Known impairment of imune function.
• Known rheumatism and autoimmune disease.
• Receipt of medicines that would affect evaluation of immunogenicity.
• Receipt of any live virus vaccination or receipt of any inactivated vaccine/toxoid prior to enrollment.
• Blood donation prior to enrollment.
• Receipt of another investigation agent prior to enrollment.
• History of alcohol or drug abuse.
• Females who are pregnant or potentially childbearing or are breastfeeding.
• Ineligible subject based on the judgement of the investigator.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
UMN-0501 45µg	UMN-0501	Recombinant H5N1 vaccine 45µg
UMN-0501 90µg	UMN-0501	Recombinant H5N1 vaccine 90µg
UMN-0501 135µg	UMN-0501	Recombinant H5N1 vaccine 135µg

Primary Outcome Measures

Name	Time	Method
Number of subjects who achieve seroconversion, seroprotection, GMTs and GMT ratio to baseline, 21 days after the 2nd vaccination defined by serum neutralizing and HAI titers against the influenza H5N1 A/Vietnam/1203/2004 virus.	Day 42: 21 days after 2nd vaccination (42 days after 1st vaccination)
Frequencies of AEs including vaccine-related reactogenicity events.	Throughout study period: Day0 to 42

Secondary Outcome Measures

Name	Time	Method
To explore T-cell response in the subset of subjects after each vaccination as determined by proliferation and cytokine production capacity of T-cells re-stimulate by H5N1 A/Vietnam/1203/2004 recombinant virus antigens.	Day0, Day 21 and Day 42

Trial Locations

Locations (2)

National Hospital Organization Tokyo Medical Center; 🇯🇵 Meguro-ku, Tokyo, Japan

National Hospital Organization Osaka Minami Medical Center; 🇯🇵 Kawachinagano City, Osaka, Japan